FSdC demonstrated statistically significant and superior improvement in disc preservation and structural integrity compared to other treatmentsHOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics ...

FibroBiologics (FBLG) announced preclinical results for FSdC, an investigational FSdC spheroid-based therapy, demonstrating superior improvement ...

On February 12, 2025, Fibrobiologics, Inc. (NASDAQ:FBLG) held an Analyst Day and provided a comprehensive update on the ...

FibroBiologics (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFUs), which ...

HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fibroblast ...

FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...

In a new finding, researchers from Barts Cancer Institute at Queen Mary University, London, have discovered more about how fibroblasts actually help pancreatic cancer develop, raising the possibility ...

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTC: FCSC) today announced that its Phase 2 study to evaluate the safety and efficacy of azficel-T (LAVIV®) for the treatment of patients with ...

A recent study published in the Nutrients Journal evaluated the effects of phenolic compounds in extra virgin olive oil (EVOO) on the proliferation, cell cycle, migration, and antigenic profile of ...